The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
What Happened: A notable Form 4 filing on Wednesday with the U.S. Securities and Exchange Commission revealed that Schorno, ...
Pfizer and its partners have granted Rigel Pharmaceuticals an exclusive license to commercialize VEPPANU (vepdegestrant), the first FDA approved oral PROTAC for advanced breast cancer. The agreement ...
Shares of Rigel Pharmaceuticals RIGL have rallied 76.7% in the past three months. This stock price rally can be attributed to growing investor confidence regarding the strong growth of the company’s ...
Shares of Rigel Pharmaceuticals (NASDAQ: RIGL) jumped 20.9% in August, according to data provided by S&P Global Market Intelligence as investors in the biotech become more comfortable with the ...
Rigel Pharmaceuticals RIGL is scheduled to report third-quarter 2025 results on Nov. 4, after market close. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $61.6 ...
(RTTNews) - Shares of Rigel Pharmaceuticals, Inc. (RIGL) are slipping over 11% in extended session on Monday after the company said it has received guidance from the U.S. Food and Drug ...
NEW YORK (AP) -- Shares of Rigel Therapeutics Inc. lost more than a third of their value Friday on mixed results from a late-stage clinical trial of a rheumatoid arthritis drug the company helped ...
Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, ...
SOUTH SAN FRANCISCO, Calif., Nov. 2, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter ended September 30, 2021, including sales of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results